This review discusses the evidence in support of the use of beclometasone dipropionate/formoterol (Fostair) for patients with asthma;, its pharmacological properties, dosage and administration, and efficacy and tolerability as demonstrated in pivotal clinical trials.
It also provides commentary and recommendations from Professor Francis Thien, Director of the Department of Respiratory and Sleep Medicine at Box Hill Hospital, Eastern Health, and the Monash University Clinical School in Melbourne, Australia.
Please login below to download this issue (PDF)